Residual nodal disease following neoadjuvant chemotherapy for upper tract urothelial carcinoma (UTUC) indicates an especially high-risk population.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy.

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications.

There have been no prospective studies comparing stent use vs nonuse after ureteroscopy for uncomplicated renal stones.

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

Data on the efficacy of radical prostatectomy in managing clinically node-positive prostate cancer have been limited.

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.